Press coverage about Windtree Therapeutics (NASDAQ:WINT) has been trending somewhat positive on Thursday, according to Accern Sentiment Analysis. Accern identifies positive and negative press coverage by monitoring more than twenty million blog and news sources. Accern ranks coverage of public companies on a scale of negative one to one, with scores closest to one being the most favorable. Windtree Therapeutics earned a coverage optimism score of 0.21 on Accern’s scale. Accern also gave media coverage about the biotechnology company an impact score of 47.5233807913924 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the company’s share price in the immediate future.

Shares of Windtree Therapeutics (WINT) traded up 0.513% during mid-day trading on Thursday, reaching $0.196. The company had a trading volume of 26,001 shares. The firm has a 50 day moving average of $0.21 and a 200-day moving average of $0.75. The stock’s market capitalization is $2.74 million. Windtree Therapeutics has a one year low of $0.18 and a one year high of $3.50.

Windtree Therapeutics (NASDAQ:WINT) last posted its earnings results on Monday, August 21st. The biotechnology company reported ($0.76) EPS for the quarter, topping analysts’ consensus estimates of ($0.99) by $0.23. The firm had revenue of $1.15 million during the quarter, compared to analysts’ expectations of $0.40 million. Analysts forecast that Windtree Therapeutics will post ($2.46) EPS for the current fiscal year.

WINT has been the topic of a number of recent research reports. Zacks Investment Research raised Windtree Therapeutics from a “hold” rating to a “buy” rating and set a $0.25 price target on the stock in a research report on Wednesday, August 30th. Stifel Nicolaus cut Windtree Therapeutics from a “buy” rating to a “hold” rating in a research report on Friday, June 30th.

TRADEMARK VIOLATION NOTICE: “Windtree Therapeutics (WINT) Earning Somewhat Favorable Press Coverage, Study Shows” was originally reported by Daily Political and is the property of of Daily Political. If you are reading this piece of content on another site, it was stolen and republished in violation of US & international trademark and copyright law. The original version of this piece of content can be viewed at

About Windtree Therapeutics

Windtree Therapeutics, Inc, formerly Discovery Laboratories, Inc, is a biotechnology company. The Company is focused on developing KL4 surfactant therapies for respiratory diseases and other potential applications. The Company operates through the research and development of products focused on surfactant therapies for respiratory disorders and diseases, and the manufacture and commercial sales of approved products segment.

Insider Buying and Selling by Quarter for Windtree Therapeutics (NASDAQ:WINT)

Receive News & Ratings for Windtree Therapeutics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Windtree Therapeutics Inc and related companies with's FREE daily email newsletter.